Ocugen, Inc. (OCGN)

1,3200 -0,1200 (-8,33%) Börsenschluss: 04:00PM EDT

Ocugen, Inc.

263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman	1,2M	1,26M	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	56,72k	N/A	1967
Mr. Michael Breininger CPA, M.B.A.	Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller	N/A	N/A	1982
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development	N/A	N/A	1983
John Kouch J.D.	General Counsel	N/A	N/A	N/A
Ms. Tiffany J. Hamilton M.B.A.	Head of Corporate Communications	N/A	N/A	N/A
Dr. Durgaprasad Annavajjula Ph.D.	VP, Head of Program Management & Chief of Staff	N/A	N/A	N/A
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial	N/A	N/A	N/A
Ms. Jyothy Pillai M.S.	Head of Regulatory & Quality	N/A	N/A	N/A
Dr. Huma Qamar CMI, M.D., M.P.H.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Corporate Governance

Ocugen, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 5, Vorstand: 7, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.